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Abstract 
IKZF1 gene deletions have been associated with a poor outcome in pediatric precursor 
B-cell acute lymphoblastic leukemia. To assess the prognostic relevance of IKZF1 
deletions for patients treated on Berlin-Frankfurt-Münster Study Group trial ALL-BFM 
2000, we screened 694 diagnostic acute lymphoblastic leukemia samples by Multiplex 
Ligation-dependent Probe Amplification. Patients whose leukemic cells beared IKZF1 
deletions had a lower 5-year event-free survival (0.69±0.05 vs. 0.85±0.01; p < 0.0001) 
compared to those without, mainly due to a higher cumulative incidence of relapses 
(0.21±0.04 vs. 0.10±0.01; p=0.001). Although IKZF1 deletions were significantly 
associated with the P2RY8-CRLF2 rearrangement, their prognostic value was found 
independent from this association. Thus, IKZF1 deletion is an independent predictor of 
treatment outcome and strong candidate marker for integration in future treatment 
stratification strategies on ALL-BFM protocols. 
Clinicaltrials.gov identifier: NCT00430118 
DOI: 10.3324/haematol.2011.056135
Introduction 
Approximately 20% of children with acute lymphoblastic leukemia (ALL) still suffer from 
relapse and may benefit from improved risk stratification and adapted treatment 
strategies. In this context, the influence of IKZF1 gene aberrations on therapeutic 
outcome has received much attention in recent investigations. IKZF1 encodes for 
Ikaros, a zinc-finger transcription factor family member, which functions sequence-
specific in transcriptional regulation and chromatin remodeling and is required for the 
development of all lymphoid lineages1-3. Somatic aberrations of IKZF1 have recurrently 
been observed in precursor B-cell ALL (pB-ALL) - most frequently in those carrying a 
BCR/ABL rearrangement - and have been shown to confer a poor treatment outcome4-
13. However, aberrations of IKZF1 were also found to associate with additional genetic 
alterations recurrently observed in childhood ALL, such as JAK mutations and 
translocations involving the chemokine receptor like factor 2 (CRLF2) gene4,7,14-18.  
Juxtaposition of CRLF2 to the IgH@ enhancer or the P2RY8 promoter lead to elevated 
expression of wild-type CRLF2 in ALL and has been shown to exert a negative 
prognostic impact on outcome17,18. However, the prognostic relevance seems to be 
treatment-dependent and it is not clear yet whether the prognostic impact of IKZF1 is 
independent of these concurrent lesions19.  
In the present study, we assessed the prognostic role of IKZF1 deletions in a large 
cohort of 694 pediatric ALL patients treated according to the ALL-BFM 2000 protocol. 
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Design and Methods 
Patients 
In accordance with institutional review board regulations, clinical samples were obtained 
from children with ALL before treatment. The study was approved by the institutional 
review board of the Hannover Medical School, Hannover, Germany, and informed 
consent obtained from patients and/or their legal guardians in accordance with the 
Declaration of Helsinki. Diagnostics, risk group assignment, and treatment were 
performed according to the ALL-BFM 2000 protocol20-22. Risk group stratification 
(standard risk, SR; intermediate risk, IR; high risk, HR) was mainly based on minimal 
residual disease (MRD) analysis after induction (time point 1, TP1) and consolidation 
therapy (TP2)20. SR patients were MRD-negative on both TP and HR patients had MRD 
levels of ≥10-3 at TP2. MRD-IR patients had positive MRD detection at either one or 
both time points but at a level of <10-3 at TP2. Patients with prednisone poor-response 
(PR; ≥ 1000 leukemic blood blasts / µ l on treatment day 8) or induction failure (≥5% 
leukemic blasts in the bone marrow, BM) or positivity for chromosomal translocations 
t(9;22)(q34;q11) or t(4;11)(q21;q23) or their molecular equivalents (BCR/ABL or 
MLL/AF4 rearrangement) were stratified into the HR group, independent of MRD.  
Consecutively enrolled patients from the ALL-BFM 2000 study population with sufficient 
spare leukemic DNA available were included in our present study (Supplementary Table 
1). BM or peripheral blood specimens had to contain more than 80% blasts, as 
assessed morphologically before gradient centrifugation.  
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Multiplex ligation-dependent probe amplification (MLPA) analysis 
Recently, it was shown that MLPA is ideal for rapid high-throughput testing of large 
cohorts with a view to establish incidence and prognostic significance of certain gene 
aberrations23. MLPA analysis was performed using the MLPA SALSA kit P335-A3 ALL-
IKZF1 (MRC-Holland, Amsterdam, The Netherlands, www.mlpa.com) according to the 
manufacturer’s protocol. The assay includes probes for each of the eight exons of the 
IKZF1 gene and is able to detect deletions of the whole gene as well as all types of 
focal intragenic deletions. Selected exons of the genes EBF1, CDKN2A/B, PAX5, ETV6, 
BTG1, RB1 and the PAR1 region (approx. 230 kBp downstream of SHOX, CRLF2, 
CSF2RA and IL3RA) are also covered. The P2RY8-CRLF2 fusion can be identified 
through assessment of CSFRA and IL3RA deletions. Fragment analyses were 
performed on an Applied Biosystems 3730 DNA Analyzer (Applied Biosystems, 
Carlsbad, CA, USA) and data analyzed using Peak Scanner v1.0 and Coffalyser v9.4 
software. Relative copy number was calculated after intra-sample normalization against 
control fragments and inter-sample normalization against control samples (healthy 
blood donor DNA). A ratio of 1±0.3 represents a normal copy number of 2, ratios <0.7 
and <0.3 represent heterozygous and homozyous deletions, respectively, while ratios 
>1.3 indicate amplifications. Ratios for all fragments were visually inspected for 
plausibility and outliers included/excluded where appropriate. In a separate cohort of 25 
patients (23 with IKZF1 deletion), we compared the results from Affymetrix SNP 6.0 
arrays with MLPA kit P335 (Online Supplementary Figure 1). All 23 deletions that were 
known from SNP 6.0 arrays were also detected by MLPA, in 19 cases with exact 
overlap concerning the deleted exons. In three cases not all exons were called correctly 
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by MLPA, probably due to subclonality of the deletions. In one additional case, the 
deletion that was found in exon 3 by MLPA was detected in intron 3 on the SNP 6.0 
array due to the location of SNP markers on the array. Comparison of the data obtained 
by the MLPA kit P335-A3 and the MLPA kit P202-A1 could be undertaken in 78 out of 
the 84 cases with IKZF1 deletions and only in one case the deletion was not detected 
using the MLPA kit P202, due to subclonality. Visual inspection of the results did not 
allow reliable detection of the lesion in P202 due to a higher background noise.  (Online 
Supplementary Figure 2).  
 
Statistical analysis 
Event-free survival (EFS) was calculated from the date of diagnosis to last follow-up or 
to the first event (no complete remission [CR] as event on day 0, relapse, secondary 
malignancy, or death of any cause). Overall survival (OS) was calculated from the date 
of diagnosis to date of death by any cause. Rates were calculated according to Kaplan-
Meier and compared by log-rank test. Cumulative incidence of relapse (CIR) functions 
were constructed by the method of Kalbfleisch and Prentice and compared by the Gray 
test. Cox regression was used to calculate the hazard ratio for an event mediated by 
IKZF1 deletions. Proportional differences between patient groups were analyzed by 
Chi2 or Fisher’s exact tests. Statistical analyses were carried out using the SPSS 
statistical package (IBM, Chicago, IL, USA) and two-sided P-values below 0.05 were 
considered to be statistically significant. 
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Results and Discussion 
Genetic aberrations in IKZF1 were screened in diagnostic specimens of 694 ALL 
patients and IKZF1 deletions were detected in 84 out of 694 samples (12%) (Table 1). 
This frequency is within the range of abundances reported in other cohorts before7,9,13. 
Twenty-nine of these deletions covered the whole gene (35%), while 55 were focal 
deletions (65%). As described previously, focal lesions detected were mainly Δ4-7 (23 
cases, 42%) and Δ2 -7 (4 cases, 7%) deletions (Table 1 and Supplementary Figure 
2)6,8,9,14,23. Δ4 -7 and Δ2 -7 deletions represent deletions of exons 4-7 and exons 2-7 
respectively. All deletions are visualised in Online Supplementary Figure 2. 
Comparing leukemic and clinical characteristics of patients with and without IKZF1 
deletion, no significant differences were observed concerning sex, age or presence of 
an MLL/AF4 rearrangement (Table 2). There was a positive association of IKZF1 
deletion with higher white blood cell counts (WBC) at diagnosis (p=0.01), pB-ALL 
immunophenotype (p = 0.01), positivity for a BCR/ABL rearrangement (p=0.03), as well 
as negativity for an ETV6/RUNX1 rearrangement (p<0.01). Of interest, only five out of 
15 BCR/ABL-positive cases harbored a deletion, which contrasts previously published 
data describing the presence of IKZF1 deletions in about 80% of BCR/ABL-positive 
ALL.5,6,8.  
Most studies published so far focused on pB-ALL, and we also see a significant 
association of IKZF1 deletions with the pB-ALL phenotype. However, our cohort 
incorporated a total of 116 T-ALL patients, 6 of which showed an IKZF1 deletion (5.2%). 
Out of the six T-ALL IKZF1-deleted patients, one was treated in the SR group, while the 
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others were HR patients. The SR patient is in CR, as are two of the HR patients, while 
the other three died (only one after a relapse). 
Whereas no significant association of IKZF1 status with PR was observed, the presence 
of IKZF1 deletions was significantly more frequent in MRD-HR patients as compared to 
MRD-IR and MRD-SR patients (p < 0.01). Five-year EFS was significantly lower in 
patients with an IKZF1 deletion compared to those without (0.69±0.05 vs. 0.85±0.01; p 
< 0.0001) (Figure 1A). This difference was mainly attributable to a significantly higher 
CIR in IKZF1-deleted patients (0.21±0.04 vs. 0.10±0.01; p=0.001) (Figure 1B). This 
effect was most pronounced in the IR group, where the 5-y EFS was 0.71±0.07 in 
IKZF1-deleted patients compared to 0.84±0.02 in those without (p=0.008). The 
corresponding CIR were 0.26±0.07 and 0.10±0.02, respectively (p=0.0002) (Figures 1D 
and 1E). Fifty percent of all events and 13 of 19 relapses (68%) occurred in the IR 
group. No significant differences in EFS were seen in SR patients (deletion-positive vs. 
negative patients: 5-y EFS 0.85±0.08 vs. 0.92±0.02, p=0.42; CIR 0.08±0.02 vs. 
0.05±0.05, p=0.54). While in HR-patients EFS was 0.46±0.11 in the IKZF1-deleted vs. 
0.69±0.05 in the non-deleted group (p=0.03), the CIR did not differ significantly 
(0.25±0.10 vs. 0.15±0.04, p=0.28). 
Five-year OS was also significantly reduced in patients with IKZF1 deletions compared 
to patients without it (0.82±0.04 vs. 0.92±0.01, p = 0.003). The differences were, 
however, not significant when analyzing the data according to the current risk groups: 
(SR: deletion-positive vs. negative patients: 5-y OS 0.99±0.01 vs. 1.00, p=0.52; IR: 
0.86±0.05 vs. 0.93±0.01, p=0.09; HR: 0.56±0.11 vs. 0.75±0.04, p=0.06). This suggests 
DOI: 10.3324/haematol.2011.056135
that patients with IKZF1 deletions who subsequently relapse are in part still treatment 
sensitive in the relapse situation.  
In a Cox regression analysis considering the additional variables sex, initial WBC, MRD, 
and presence of the MLL/AF4, BCR/ABL and ETV6/RUNX1 rearrangement, IKZF1 
deletions provided independent prognostic information (hazard ratio for an event 2.28, 
95% confidence interval, CI, 1.44-3.60; p < 0.001, Online Supplementary Table 2).  
IKZF1 deletions have been described to be associated with rearrangements of CRLF2 
and, recently, we have shown that the P2RY8-CRLF2 rearrangement is associated with 
a poor outcome in patients treated according to the ALL-BFM 2000 protocol17. In the 
study presented here, we confirmed a significantly higher number of IKZF1 deletions in 
patients positive for the P2RY8-CRLF2 rearrangement (13.1%) in comparison to those 
negative (2.6%; p<0.001). To explore whether IKZF1 has prognostic relevance 
independent of CRLF2 status, we first excluded CRLF2-rearranged patients from the 
multivariate analysis accounting for the strong association of the two factors (IKZF1 
deletion and P2RY8-CRLF2 rearrangement), and the resulting co-linearity in the model. 
In this analysis, IKZF1 deletions still provided independent prognostic information 
(hazard ratio for an event 1.94, 95% CI 1.19-3.16; p = 0.008). Cox regression analysis 
including both factors resulted in a hazard ratio of 2.08 (95% CI 1.32 – 3.28, p=0.002) 
for IKZF1-deletions and a hazard ratio of 2.04 (95% CI 0.94 – 4.41, p=0.07) for P2RY8-
CRLF2 (Online Supplementary Tables 3-4). 
Comparing clinical and biological characteristics of patients with whole and focal gene 
deletions, no significant differences for sex, WBC, immunophenotype, involvement of 
the central nervous system (CNS), presence of BCR/ABL, MLL/AF4 or ETV6/RUNX1 
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rearrangements, PR, MRD and final risk stratification were observed (data not shown). 
Patients with focal deletions were significantly older compared to patients with whole 
gene deletions (>10 years: 38% vs. 10%; p=0.01). There were no significant differences 
in 5-year EFS or CIR neither comparing whole and focal deletions nor comparing the 
different types of IKZF1 deletions (data not shown).  
IKZF1 deletions were repeatedly reported to confer an increased risk of relapse and 
poor outcome in selected cohorts6,9 and, recently, in an unselected cohort of 131 pB-
ALL cases12,13. Here, we present data on the prognostic relevance of IKZF1 in a large 
set of nearly 700 patients uniformly treated on the MRD-based ALL-BFM 2000 protocol 
and were able to show that IKZF1 status exerts additive value as a prognostic factor - 
especially in the IR group in which still the majority of relapses occurs. Therefore, the 
assessment of IKZF1 status may contribute to a molecular-based stratification algorithm 
aiming at improving outcome for children suffering from ALL. However, more work has 
to be done to elucidate the molecular differences between IKZF1-deleted leukemias of 
patients who relapse and those who don’t. From our perspective, this is a prerequisite 
for an application of the IKZF1 status in clinical decision making. 
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 Tables and Figures 
Table 1. MLPA analysis of IKZF1 deletions in 694 patients with pediatric ALL.  
 
IKZF1 status Patients, n % 
Not-deleted 610 88 
Deleted1 84 12 
   Whole gene 29 35 
   Focal 55 65 
      Δ4-7 deletion 23 42 
      Δ2-7 deletion 4 7 
      Other focal deletion 28 51 
1Deletions are divided into whole gene and focal deletions while focal deletions are divided into three 
subgroups. Δ4-7 and Δ 2-7 deletions represent deletions of exons 4-7 and exons 2-7 respectively, 
following the nomenclature of NCBI. All deletions are visualised in Supplementary Table 3.   
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Table 2. Patient characteristics and response to treatment according to IKZF1 deletion 
status in 694 pediatric patients with ALL.  
 
Feature IKZF1 not 
deleted     n (%) 
IKZF1 deleted      
n (%) 
p1 
Number of patients 610 (100) 84 (100)  
Sex   0.91 
   Male 353 (57.9) 48 (57.1)  
   Female 257 (42.1) 36 (42.9)  
Age at diagnosis (years)   0.42 
   1 – 9 460 (75.4) 60 (71.4)  
   ± 10 150 (24.6) 24 (28.6)  
Presenting WBC count (x1010/L)   0.01 
   < 1 237 (38.9) 19 (22.6)  
   1 – 4.99 222 (36.4) 35 (41.7)  
   5 – 9.99 83 (13.6) 14 (16.7)  
   ≥ 10 68 (11.1) 16 (19.0)  
Prednisone response2   0.99 
   Good 529 (86.7) 71 (84.5)  
   Poor 78 (12.8) 10 (11.9)  
   No information 3 (0.5) 3 (3.6)  
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 MRD3   <0.01 
   MRD-SR 226 (37.0) 23 (27.4)  
   MRD-IR 241 (39.5) 35 (41.7)  
   MRD-HR 32 (5.2) 15 (17.9)  
   No information 111 (18.3) 11 (13.0)  
Immunology   0.01 
   Non-T-ALL 496 (81.3) 76 (90.5)  
   T-ALL 110 (18.0) 6 (7.1)  
   No information 4 (0.7) 2 (2.4)  
ETV6/RUNX1   <0.01 
   Negative 423 (69.3) 76 (90.5)  
   Positive 141 (23.1) 4 (4.75)  
   No information 46 (7.6) 4 (4.75)  
BCR/ABL1   0.03 
   Negative 590 (96.7) 78 (92.9)  
   Positive 10 (1.6) 5 (5.9)  
   No information 10 (1.6) 1 (1.2)  
MLL/AF4   0.99 
   Negative 570 (93.4) 81 (96.4)  
   Positive 1 (0.2) 0  
   No information 39 (6.4) 3 (0.6)  
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 Final risk group   0.06 
   SR 219 (35.9) 21 (25.0)  
   IR 288 (47.2) 42 (50.0)  
   HR 103 (16.9) 21 (25.0)  
¹Χ2 test comparing IKZF1 normal and deleted groups, patients with no information excluded from test; 
²good: less than 1000 leukemic blood blasts / µl on treatment day 8, poor: more than 1000 / µl. 
3MRD risk groups17: MRD-SR: TP1+2 negative, MRD-IR: TP1 and/or TP2 <10-3, MRD-HR: TP2 ≥10-3. 
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Figure legend 
Figure 1. Treatment outcome of patients with pediatric ALL comparing patients with 
and without IKZF1 deletions. For the whole cohort of 694 patients the Kaplan-Meier 
estimates of event free survival (EFS) at 5 years (A), cumulative incidence of relapse 
(CIR) at 5 years (B) and overall survival (OS) at 5 years (C) are displayed. Also, for the 
intermediate risk group, EFS (D), CIR (E) and OS (F) are shown. 
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Figure 1.  
                                                                    
  
                                                                                        
 
 
 
                                                                                                 
 
 
 
 
                                                                                                    
 
                                                                                                      
 
 
 
 
 
 
A 
B 
C 
D 
E 
F 
DOI: 10.3324/haematol.2011.056135
1 
 
Online Supplementary Appendix 
 
 
 
Online Supplementary Figure 1. Comparison of results from Affymetrix SNP 6.0 
arrays and MLPA kit P335, regarding IKZF1 deletions, in 25 selected patients. 
 
Online Supplementary Figure 2. Results for all 84 IKZF1 deleted patients as 
analysed with MLPA kit P335 and validation with MLPA kit P202. 
 
Online Supplementary Table 1. Patient characteristics and response to treatment 
in the study cohort of 694 pediatric patients with ALL, in comparison to the remaining 
ALL-BFM 2000 patient cohort that was not studied. 
 
Online Supplementary Table 2. Multivariate cox regression analysis for event-free 
survival, including all 694 patients. 
 
Online Supplementary Table 3. Multivariate cox regression analysis for event-free 
survival, excluding 27 P2RY8-CRLF2 positive patients from the cohort. 
 
Online Supplementary Table 4. Multivariate cox regression analysis for event-free 
survival, including P2RY8-CRLF2 status in the model. 
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Online Supplementary Table 1. Patient characteristics and response to treatment 
in the study cohort of 694 pediatric patients with ALL, in comparison to the remaining 
ALL-BFM 2000 patient cohort that was not studied. 
Feature Cohort not 
studied (%) 
Study cohort 
(%) 
P1 
Number of patients 2133 (100) 694 (100)  
Sex   0.20 
   Male 1170 (54.9) 400 (57.6)  
   Female 963 (45.1) 294 (42.4)  
Age at diagnosis (years)   0.90 
   1 – 9 1603 (75.2) 520 (74.9)  
   ± 10 530 (24.8) 174 (25.1)  
Presenting WBC count (x1010/L)   <0.0001 
   < 1 1091 (51.1) 257 (37.0)  
   1 – 4.99 666 (31.2) 256 (36.9)  
   5 – 9.99 175 (8.2) 97 (14.0)  
   ≥ 10 201 (9.4) 84 (12.1)  
Prednisone response2   0.005 
   Good 1920 (90.0) 601 (86.7)  
   Poor 189 (8.9) 87 (12.5)  
   No information 24 (1.1) 6 (0.8)  
MRD3   0.57 
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   MRD-SR 687 (32.2) 249 (35.9)  
   MRD-IR 847 (39.7) 276 (39.8)  
   MRD-HR 132 (6.2) 46 (6.6)  
   No information 467 (21.9) 123 (17.7)  
Immunology   0.03 
   Non-T-ALL 1787 (83.8) 572 (82.5)  
   T-ALL 280 (13.1) 116 (16.6)  
   No information 66 (3.1) 6 (0.9)  
ETV6/RUNX1   0.80 
   Negative 1488 (69.8) 498 (71.7)  
   Positive 449 (21.0) 146 (21.1)  
   No information 196 (9.2) 50 (7.2)  
BCR/ABL   0.58 
   Negative 2053 (96.2) 668 (96.2)  
   Positive 39 (1.8) 15 (2.2)  
   No information 41 (2.0) 11 (1.6)  
MLL/AF4   0.23 
   Negative 1979 (92.8) 651 (93.8)  
   Positive 10 (0.5) 1 (0.1)  
   No information 144 (6.7) 42 (6.1)  
Final risk group   0.003 
   SR 667 (31.3) 240 (34.6)  
   IR 1167 (54.7) 331 (47.7)  
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   HR 299 (14.0) 123 (17.7)  
¹Χ2 test comparing study cohort and patients not studied, patients with no information excluded from test; 
²good: less than 1000 leukemic blood blasts / µl on treatment day 8, poor: more than 1000 / µl. 
3MRD risk groups17: MRD-SR: TP1+2 negative, MRD-IR: TP1 and/or TP2 <10-3, MRD-HR: TP2 ≥10-3. 
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Online Supplementary Figure 1. Comparison of results from Affymetrix SNP 6.0 
arrays and MLPA kit P335, regarding IKZF1 deletions, in 25 selected patients1.  
SNP 6.0 MLPA P335 
IKZF1-Exon IKZF1-Exon 
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 
                
                
                
                
                
                
                
                
                
                
                
                
  In3(2)              
                
                
                
                
                
                
                
                
                
                
                
                
1Each row represents one patient (the first two patients were chosen as negative controls), each coloured 
lane represents a deletion in the respective exon. Light red deletions are heterozygous, dark red deletions 
are homozygous and light pink deletions are subclonal. 
2Deletion on SNP 6.0 was found in Intron 3. 
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Online Supplementary Figure 2. Results for 78 IKZF1 deleted patients as 
analysed with MLPA kit P335 and validation with MLPA kit P2021. 
MLPA P335 
 
MLPA P202 
IKZF1- Exon IKZF1-Exon 
1 2 3 4 5 6 7 8 1 1 1 2 2 3 3 3 4 4 5 5 6 6 7 7 8 8 
        a b c a b a b In2 a b a b a b a b a b 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1MLPA kit P202-A1 contains additional markers, compared to kit P335-A3, identical markers are 
highlighted in bold. Each row represents one patient, each coloured lane represents a deletion in the 
respective exon. Light red deletions are heterozygous, dark red deletions are homozygous and light pink 
deletions are subclonal. In one subclonal sample, results were discordant between P335 and P202, as 
indicated. Of the six un-validated samples four had a Δ1-8, one a Δ4-7 and one a Δ5-7 deletion in P335.  
2In: Intron. 
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Online Supplementary Table 2. Multivariate cox regression analysis for event-free 
survival, including all 694 patients. 
Feature Hazard ratio 95% CI p 
IKZF1 2.28 1.44 – 3.60 < 0.0001 
Sex 0.91 0.62 – 1.33 0.62 
SR 0.56 0.34 – 0.93 0.03 
HR 1.91 1.20 – 3.03 0.006 
ETV6/RUNX1 1.00 0.58 – 1.73 0.99 
Immunology 0.99 0.59 – 1.67 0.97 
WBC ≥ 100,000 1.46 0.89 – 2.39 0.14 
 
 
Online Supplementary Table 3. Multivariate cox regression analysis for event-free 
survival, excluding 27 P2RY8-CRLF2 positive patients from the cohort. 
Feature Hazard ratio 95% CI p 
IKZF1 1.94 1.19 – 3.16 0.008 
Sex 0.91 0.61 – 1.34 0.62 
SR 0.58 0.34 – 0.99 0.05 
HR 1.98 1.24 – 3.17 0.004 
ETV6/RUNX1 1.03 0.59 – 1.79 0.92 
WBC ≥ 100,000 1.53 0.93 – 2.51 0.09 
 
DOI: 10.3324/haematol.2011.056135
8 
 
Online Supplementary Table 4. Multivariate cox regression analysis for event-free 
survival, including P2RY8-CRLF2 status in the model. 
Feature Hazard ratio 95% CI p 
IKZF1 2.08 1.32 – 3.28 0.002 
P2RY8-CRLF2 2.04 0.94 – 4.41 0.07 
Sex 0.90 0.62 – 1.32 0.591 
SR 0.54 0.33 – 0.91 0.02 
HR 2.07 1.31 – 3.28 0.002 
ETV6/RUNX1 1.07 0.60 – 1.85 0.81 
WBC ≥ 100,000 1.44 0.89 – 2.32 0.14 
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